Objective To investigate the effect of liraglutide on the inflammatory cytokine interleukin-lβ (IL-1β) and apoptohc factor caspase-3 expression in the pancreatic islets of OLETF rats with impaired glucose tolerance.Methods Twelve-week-old OLETF rats were randomized into 4 groups and received intraperitoneal injections of saline or liraglutide at 50,100,or 200 μg/kg twice daily for 12 weeks.Eight LETO rats served as the normal control group and received saline injection.After the treatments,the rats were examined for fasting and 30 min plasma insulin during OGTT test,and the expression levels of IL-1{5 and caspase-3 mRNA and protein in the pancreatic islets were detected by real-time PCR and Western blotting,respectively.Results Compared with the saline group,liraglutide significantly decreased the expressions of IL-1β and caspase-3 mRNA and protein,and significantly improved the blood glucose,islet β function and early-phase insulin secretion index in OLETF rats.Conclusion Liraglutide can improve islet function and glucose metabolism partially by inhibiting islet IL-lβ expression to delay or prevent the development of diabetes in OLETF rats.%目的 观察利拉鲁肽对糖耐量异常大鼠胰岛炎症因子白细胞介素-1β(IL-1p)和凋亡基因caspase3表达的影响.方法 12周龄糖耐量异常OLETF大鼠分为生理盐水组和不同剂量利拉鲁肽干预组(50、100、200μg/kg),8只LETO作为正常对照组.实验12周结束时,所有大鼠均检测糖耐量试验空腹及服糖后30 ruin胰岛素,并检测胰岛IL-1β和caspase3mRNA和蛋白水平.结果 利拉鲁肽干预的糖耐量异常大鼠和生理盐水干预组相比,胰岛IL-1p和caspase3表达显著降低,血糖、胰岛β细胞功能及早期胰岛素分泌指数明显改善.结论 利拉鲁肽可能通过抑制胰岛IL-1β炎症因子表达,从而改善胰岛功能及糖代谢,延缓或阻止糖尿病发生发展.
展开▼
